Abstract:Background Existing studies of PLK1 in cervical cancer had several flaws. The methods adopted by those studies of detecting PLK1 expression in cervical cancer were single and there lacks comprehensive evaluation of the clinico-pathological significance of PLK1 in cervical cancer. Methods A total of 303 cervical tissue samples were collected for in-house tissue microarrays. Immunohistochemistry was performed for evaluating PLK1 expression between cervical cancer (including cervical squamous cell carcinoma (CESC) and cervical adenocarcinoma) and non-cancer samples. The Expression Atlas database was searched for querying PLK1 expression in different cervical cancer cell lines and different tissues in the context of pan-cancer. Standard mean difference (SMD) was calculated and the summarized receiver’s operating characteristics (SROC) curves were plotted for integrated tissue microarrays, exterior high-throughput microarrays and RNA sequencing data as further verification. The effect of PLK1 expression on the overall survival, disease-free survival and event-free survival of cervical cancer patients was analyzed through Kaplan Meier survival curves for cervical cancer patients from RNA-seq and GSE44001 datasets. The gene mutation and alteration status of PLK1 in cervical cancer was inspected in COSMIC and cBioPortal databases. Functional enrichment analysis was performed for genes correlated with PLK1 from aggregated RNA-seq and microarrays. Results A total of 963 cervical cancer samples and 178 non-cancer samples were collected from in-house tissue microarrays and exterior microarrays and RNA-seq datasets. The combined expression analysis supported overexpression of PLK1 in CESC, cervical adenocarcinoma and all types of cervical cancer (SMD = 1.59, 95%CI [0.56–2.63]; SMD = 2.99, 95%CI [0.75–5.24]; SMD = 1.57, 95% CI [0.85–2.29]) and the significant power of PLK1 expression in distinguishing CESC or all types of cervical cancer samples from non-cancer samples (AUC = 0.94, AUC = 0.92). Kaplan-Meier survival curves showed that the event-free survival rate of cervical cancer patients with higher expression of PLK1 was shorter than that of patients with lower PLK1 (HR = 2.020, P = 0.0197). Genetic alteration of PLK1 including missense mutation and mRNA low occurred in 6% of cervical cancer samples profiled in mRNA expression. Genes positively or negatively correlated with PLK1 were mainly assembled in pathways such as DNA replication, cell cycle, mismatch repair, Ras signaling pathway, melanoma, EGFR tyrosine kinase inhibitor resistance and homologous recombination ( P < 0.05). Conclusions Here, we provided sufficient evidence of PLK1 overexpression in cervical cancer. The overexpression of PLK1 in cervical cancer and the contributory effect of it on clinical progression indicated the hopeful prospect of PLK1 as a biomarker for cervical cancer.

Measurement of the Mrna Level of Polo-like Kinase 1 in Bronchoscopic Bioptic Specimens by Real-Time Quantitative PCR

THE EXPRESSION AND CLINICAL SIGNIFICANCE OF CYTOKERATIN 20 mRNA IN CENTRAL VEIN BLOOD OF PATIENTS WITH GASTRIC CANCER BY RT-PCR

Polo like kinase 1 expression in cervical cancer tissues generated from multiple detection methods

Quantitative analysis of epidermal growth factor receptor mRNA in laryngeal carcinoma by reverse transcription-real time polymerase chain reaction with TagMan probe]

[Relative Quantification of Cytokeratin 19 Transcription in Oral Squamous Cell Carcinoma Tissues by Fluorescent Quantitive Real-Time RT-PCR].

Detection of RRM1,ERCC1 and BRCA1 Gene Expression in Non-Small Cell Lung Cancer Tissues and Peripheral Blood by SYBR Real-Time Fluorescent Quantitative PCR

The abnormal expression and the clinicopathologic significance of Polo-like kinase 1 ( PLK1 ) in adenocarcinoma of the lung

Clinical significance of CEA and CK20 expression in exfoliated cells by fiberoptic bronchoscopy brushing

Study on the correlationship between CK19mRNA and CyFRA21-1 in peripheral blood of lung cancer patients

[Expression of PEDF Mrna in Non-Small Cell Lung Cancer by Real-Time PCR Method].

The Anticipating Value of PLK1 for Diagnosis, Progress and Prognosis and Its Prospective Mechanism in Gastric Cancer: a Comprehensive Investigation Based on High-Throughput Data and Immunohistochemical Validation

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

The BRCA1 Mrna and RAP80 Mrna Expression Levels in Relation to Clinicopathological Characteristics in Advanced Non-Small Cell Lung Cancer

Clinical Significance of RKIP Mrna Expression in Non-Small Cell Lung Cancer

A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer.

Up-regulation of Polo-like Kinase 1 in Nasopharyngeal Carcinoma Tissues: a Comprehensive Investigation Based on RNA-sequencing, Gene Chips, and In-House Tissue Arrays.

Detection and quantitation of CK19 mRNA in the peripheral blood and regional lymph nodes of lung cancer patients

Detection of CK19mRNA in the Peripheral Blood of Lung Cancer Patients by Fluorogenic Quantitative Reverse Transcripition-Polymerase Chain Reaction

Detection of Micrometastases of Non-small Cell Lung Cancer by Using CK19 mRNA and LUNX mRNASpecific Reverse Transcription-polymerase Chain Reaction

Detection of Micrometastases of Lung Cancer by Using Lunx Mrna Specific Reverse Transcription-Polymerase Chain Reaction

Diagnostic Utility of LunX Mrna in Peripheral Blood and Pleural Fluid in Patients with Primary Non-Small Cell Lung Cancer